Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The reticuloendothelial system (RES), also known as the mononuclear phagocyte system, is a network of specialized cells primarily responsible for the clearance of foreign particles, pathogens, and cellular debris from the bloodstream and tissues. It comprises macrophages, monocytes, and specialized endothelial cells, predominantly found in the liver (Kupffer cells), spleen, lymph nodes, bone marrow, and lungs. The RES plays a crucial role in phagocytosis, immune regulation, and clearance of various substances. Dysfunction or overload of the RES can occur in conditions such as sepsis and trauma. In drug delivery, the RES often leads to rapid sequestration of nanoparticles, posing a challenge for targeted therapies.
N/A - The RES is a system, not a single molecule with a specific mechanism of action. Drug interactions primarily involve uptake and sequestration by RES cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reticuloendothelial Cell System (RES).